中文

← All funding rounds

Noetik

United StatesDrug discoverySan Francisco, United StatesPrivate

Website · noetik.ai ↗

Trains self-supervised 'virtual cell' models (OCTO) on its own spatial profiling of human tumours to find cancer targets and match drugs to patients.

Disclosed total$54M
Rounds on record2
Latest round$40MSeries A · 2024-08-29
Last stated valuationNone stated
Investors named20
Research on record1highest level 3 · Checked against existing evidence

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date202420252026$14M$40MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series A, 2024-08-29: the record then held no research entry for the company. The first research entry is dated 2026-06-15; the highest level so far is 3 (Checked against existing evidence).

Rounds and research, on one timeline

  1. 2026-06-15
    Research

    Level 3 · Checked against existing evidence

    Noetik's TARIO-2 picked out likelier responders to Agenus's BOT+BAL immunotherapy from routine biopsy slides, looking back at 49 colorectal cancer patients in a trial

    It tests whether a model that learned spatial biology can read a drug response off the cheapest slide in cancer care. The answer here is a hindsight analysis of a small, fully enrolled trial: 49 patients in the main group, a model fitted to those patients' own outcomes under cross-validation, written by Noetik with the drug's own developer and not peer-reviewed. Ovarian cancer and sarcoma looked similar but did not reach significance. Only a prospective trial that selects patients this way would show it works.

    Timeline entry →noetik.ai ↗

  2. 2024-08-29Series A
    Round

    $40M

    For: expand the spatial cancer atlas and train OCTO models

    Data generationModels and platform

    Lead · Polaris Partners ✓Khosla VenturesWittington Ventures ✓Breakout Ventures ✓DCVC ✓Zetta Venture Partners ✓Catalio Capital Management ✓11.2 CapitalEpic VenturesIntermountain VenturesNorth South VenturesApSTAT TechnologiesLinearis Labs and Ventures FundJean-Francois Gagne

    On the deal: Amy Schulman (Managing Partner, Polaris Partners, joins the board); James Hardiman (General Partner, DCVC); Jean-Francois Gagne (Angel investor)

    Announced by the company · dcvc.com ↗

  3. 2023-09-07Seed
    Round

    $14M

    For: generate human tumour data and build transformer models

    Data generationModels and platform

    Lead · DCVC ✓Zetta Venture Partners ✓11.2 CapitalCatalio Capital Management ✓Epic VenturesIntermountain VenturesChris Gibson (Recursion CEO)North South VenturesChau KhuongCJNV BioVenturesViswa ColluruHummingbird Nomads FundMichael Secora

    On the deal: Chau Khuong (Angel investor); Chris Gibson (Angel investor); Dylan Reid (Partner, Zetta Venture Partners); James Hardiman (General Partner, DCVC); Michael Secora (Angel investor); Viswa Colluru (Angel investor)

    The investor's own page says · DCVC: 2023

    Announced by the company · biospace.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

Its investors also backed

Other companies on this page whose rounds name the same investor.